Windtree Therapeutics has announced its delisting from Nasdaq after failing to meet minimum share price requirements. This event affects the market and the company's future trading operations.
Reasons for Delisting from Nasdaq
Windtree Therapeutics was put on notice on August 19, 2025, for not meeting the minimum price requirements set by Nasdaq Listing Rule 5550(a)(2). As a result, the company's shares, ticker symbol WINT, will cease trading on Nasdaq on August 21, 2025.
Future Trading Plans
Following its delisting, Windtree Therapeutics plans to begin trading on the OTC (over-the-counter) market. The company has applied for OTC Markets' OTCQB platform, but approval is not guaranteed.
Impact on the Company and Operations
Windtree Therapeutics stated that this transition will not impact its operations. The company will continue to file reports with the U.S. Securities and Exchange Commission (SEC). It has also previously warned investors about potential risks and uncertainties in documents filed with the SEC.
Windtree Therapeutics continues its operations despite its delisting from Nasdaq. The future of its trading and market positions remain in question.
